Hong Zhao insider trades: Sciclone Pharmaceuticals (SCLN) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Hong reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 16, 2017 | SCLN | ↓ Sell | 30,000 | $11.00 | $330K | Direct | Aug 16, 2017 (0d) |
| Jun 12, 2017 | SCLN | ↓ Sell | 40,500 | $10.75 | $435K | Direct | Jun 14, 2017 (2d) |
| Mar 15, 2017 | SCLN | ↓ Sell | 3,000 | $9.60 | $29K | Direct | Mar 17, 2017 (2d) |
| Aug 12, 2016 | SCLN | ↓ Sell | 40,500 | $10.41 | $422K | Direct | Aug 16, 2016 (4d) |
| Jun 8, 2015 | SCLN | ↓ Sell | 10,000 | $9.23 | $92K | Direct | Jun 9, 2015 (1d) |
| May 14, 2015 | SCLN | ↓ Sell | 12,500 | $9.07 | $113K | Direct | May 18, 2015 (4d) |
| May 16, 2014 | SCLN | ↓ Sell | 12,500 | $4.75 | $59K | Direct | May 16, 2014 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Hong Zhao's insider trades
Hong Zhao is CEO, China Operations at Sciclone Pharmaceuticals (SCLN). Since May 16, 2014, Hong has reported no open-market purchases and 7 sales worth $1.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings), option exercises (8 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SCLN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.